These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 2249377

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical pharmacology of adinazolam and N-desmethyladinazolam mesylate following single intravenous infusions of each compound in health volunteers.
    Fleishaker JC, Hulst LK, Smith TC, Friedman H.
    Eur J Clin Pharmacol; 1992; 42(3):287-94. PubMed ID: 1577047
    [Abstract] [Full Text] [Related]

  • 3. Adinazolam pharmacokinetics and behavioral effects following administration of 20-60 mg oral doses of its mesylate salt in healthy volunteers.
    Fleishaker JC, Phillips JP.
    Psychopharmacology (Berl); 1989; 99(1):34-9. PubMed ID: 2506603
    [Abstract] [Full Text] [Related]

  • 4. Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers.
    Venkatakrishnan K, Culm KE, Ehrenberg BL, Harmatz JS, Corbett KE, Fleishaker JC, Greenblatt DJ.
    J Clin Pharmacol; 2005 May; 45(5):529-37. PubMed ID: 15831776
    [Abstract] [Full Text] [Related]

  • 5. Effects of probenecid on the pharmacokinetics and pharmacodynamics of adinazolam in humans.
    Golden PL, Warner PE, Fleishaker JC, Jewell RC, Millikin S, Lyon J, Brouwer KL.
    Clin Pharmacol Ther; 1994 Aug; 56(2):133-41. PubMed ID: 8062489
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and pharmacodynamics of adinazolam and N-desmethyladinazolam after oral and intravenous dosing in healthy young and elderly volunteers.
    Fleishaker JC, Hulst LK, Ekernäs SA, Grahnén A.
    J Clin Psychopharmacol; 1992 Dec; 12(6):403-14. PubMed ID: 1474178
    [Abstract] [Full Text] [Related]

  • 8. Multiple-dose pharmacokinetics and pharmacodynamics of adinazolam in elderly subjects.
    Fleishaker JC, Phillips JP, Smith TC, Smith RB.
    Pharm Res; 1989 May; 6(5):379-86. PubMed ID: 2748528
    [Abstract] [Full Text] [Related]

  • 9. The pharmacokinetics and pharmacodynamics of adinazolam: multi-ethnic comparisons.
    Ajir K, Smith M, Lin KM, Fleishaker JC, Chambers JH, Anderson D, Nuccio I, Zheng Y, Poland RE.
    Psychopharmacology (Berl); 1997 Feb; 129(3):265-70. PubMed ID: 9084065
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic and pharmacodynamic comparison of immediate-release and sustained-release adinazolam mesylate tablets after single- and multiple-dose administration.
    Fleishaker JC, Wright CE.
    Pharm Res; 1992 Apr; 9(4):457-63. PubMed ID: 1495889
    [Abstract] [Full Text] [Related]

  • 11. The lack of effect of smoking on the pharmacokinetics and pharmacodynamics of adinazolam and N-demethyladinazolam.
    Chambers JH, Fleishaker JC.
    Biopharm Drug Dispos; 1994 May; 15(4):263-72. PubMed ID: 8068865
    [Abstract] [Full Text] [Related]

  • 12. Psychomotor and memory effects of two adinazolam formulations assessed by a computerized neuropsychological test battery.
    Fleishaker JC, Sisson TA, Sramek JJ, Conrad J, Veroff AE, Cutler NR.
    J Clin Pharmacol; 1993 May; 33(5):463-9. PubMed ID: 8331205
    [Abstract] [Full Text] [Related]

  • 13. Effect of food on the bioavailability of adinazolam from a sustained release formulation: effect of meal timing and lack of dose dumping.
    Fleishaker JC, Phillips JP, Lau HS.
    Biopharm Drug Dispos; 1990 Nov; 11(8):715-27. PubMed ID: 2271747
    [Abstract] [Full Text] [Related]

  • 14. Extent and variability of the first-pass elimination of adinazolam mesylate in healthy male volunteers.
    Fleishaker JC, Friedman H, Pollock SR.
    Pharm Res; 1991 Feb; 8(2):162-7. PubMed ID: 2023863
    [Abstract] [Full Text] [Related]

  • 15. Comparison of adinazolam pharmacokinetics and effects in healthy and cirrhotic subjects.
    Kroboth PD, Maxwell RA, Fleishaker JC, Van Thiel DH, Smith RB.
    J Clin Pharmacol; 1991 Jun; 31(6):580-6. PubMed ID: 1880225
    [Abstract] [Full Text] [Related]

  • 16. Relationship between concentrations of adinazolam and its primary metabolite in plasma and therapeutic/untoward effects in the treatment of panic disorder.
    Fleishaker JC, Greist JH, Jefferson JW, Sheridan AQ.
    J Clin Psychopharmacol; 1994 Feb; 14(1):28-35. PubMed ID: 8151001
    [Abstract] [Full Text] [Related]

  • 17. N-desmethyladinazolam pharmacokinetics and behavioral effects following administration of 10-50 mg oral doses in healthy volunteers.
    Fleishaker JC, Smith TC, Friedman H, Phillips JP.
    Psychopharmacology (Berl); 1991 Feb; 105(2):181-5. PubMed ID: 1796125
    [Abstract] [Full Text] [Related]

  • 18. Influence of repeated administration of cimetidine on the pharmacokinetics and pharmacodynamics of adinazolam in healthy subjects.
    Hulhoven R, Desager JP, Cox S, Harvengt C.
    Eur J Clin Pharmacol; 1988 Feb; 35(1):59-64. PubMed ID: 3220095
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of the Abbott TDx serum benzodiazepine immunoassay for the analysis of lorazepam, adinazolam, and N-desmethyladinazolam.
    Fraser AD, Bryan W.
    J Anal Toxicol; 1995 Sep; 19(5):281-4. PubMed ID: 7500613
    [Abstract] [Full Text] [Related]

  • 20. Effects of adinazolam and diazepam, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers.
    Linnoila M, Stapleton JM, Lister R, Moss H, Lane E, Granger A, Greenblatt DJ, Eckardt MJ.
    Eur J Clin Pharmacol; 1990 Sep; 38(4):371-7. PubMed ID: 2344860
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.